

Covid-19 Impact on Global Drugs for Oncology Market Size, Status and Forecast 2020-2026

<https://marketpublishers.com/r/CC07D7E2A923EN.html>

Date: June 2020

Pages: 132

Price: US\$ 3,900.00 (Single User License)

ID: CC07D7E2A923EN

Abstracts

Drugs for Oncology market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Drugs for Oncology market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 200 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Drugs for Oncology market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

This report also analyzes the impact of Coronavirus COVID-19 on the Drugs for Oncology industry.

The key players covered in this study

Roche

Celgene

Novartis

Bristol-Myers Squibb

Johnson & Johnson

Merck & Co.

AstraZeneca

Pfizer

Amgen

Eli Lilly

AbbVie

Takeda

Astellas

Ipsen

Sanofi

Bayer

Biogen Idec

Teva

Otsuka

Eisai

Merck KGaA

Gilead Sciences

Market segment by Type, the product can be split into

Chemotherapy

Targeted Therapy

Immunotherapy (Biologic Therapy)

Hormonal Therapy

Others

Market segment by Application, split into

Blood Cancer

Breast Cancer

Gastrointestinal Cancer

Prostate Cancer

Respiratory/Lung Cancer

Others

Market segment by Regions/Countries, this report covers

North America

Europe

China

Japan

Southeast Asia

India

Central & South America

The study objectives of this report are:

To analyze global Drugs for Oncology status, future forecast, growth opportunity, key market and key players.

To present the Drugs for Oncology development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

To strategically profile the key players and comprehensively analyze their development plan and strategies.

To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Drugs for Oncology are as follows:

History Year: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

- 1.1 Study Scope
- 1.2 Key Market Segments
- 1.3 Players Covered: Ranking by Drugs for Oncology Revenue
- 1.4 Covid-19 Implications on Market by Type
 - 1.4.1 Global Drugs for Oncology Market Size Growth Rate by Type: 2020 VS 2026
 - 1.4.2 Chemotherapy
 - 1.4.3 Targeted Therapy
 - 1.4.4 Immunotherapy (Biologic Therapy)
 - 1.4.5 Hormonal Therapy
 - 1.4.6 Others
- 1.5 Market by Application
 - 1.5.1 Global Drugs for Oncology Market Share by Application: 2020 VS 2026
 - 1.5.2 Blood Cancer
 - 1.5.3 Breast Cancer
 - 1.5.4 Gastrointestinal Cancer
 - 1.5.5 Prostate Cancer
 - 1.5.6 Respiratory/Lung Cancer
 - 1.5.7 Others
- 1.6 Coronavirus Disease 2019 (Covid-19): Drugs for Oncology Industry Impact
 - 1.6.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections
 - 1.6.2 Covid-19 Impact: Commodity Prices Indices
 - 1.6.3 Covid-19 Impact: Global Major Government Policy
- 1.7 Study Objectives
- 1.8 Years Considered

2 GLOBAL GROWTH TRENDS

- 2.1 Covid-19 Implications on Global Drugs for Oncology Market Perspective (2015-2026)
- 2.2 Covid-19 Implications on Global Drugs for Oncology Growth Trends by Regions
 - 2.2.1 Drugs for Oncology Market Size by Regions: 2015 VS 2020 VS 2026
 - 2.2.2 Drugs for Oncology Historic Market Share by Regions (2015-2020)
 - 2.2.3 Drugs for Oncology Forecasted Market Size by Regions (2021-2026)
- 2.3 Industry Trends and Growth Strategy
 - 2.3.1 Market Top Trends

- 2.3.2 Market Drivers
- 2.3.3 Market Challenges
- 2.3.4 Porter's Five Forces Analysis
- 2.3.5 Drugs for Oncology Market Growth Strategy
- 2.3.6 Primary Interviews with Key Drugs for Oncology Players (Opinion Leaders)

3 COVID-19 IMPLICATIONS ON COMPETITION LANDSCAPE BY KEY PLAYERS

- 3.1 Global Top Drugs for Oncology Players by Market Size
 - 3.1.1 Global Top Drugs for Oncology Players by Revenue (2015-2020)
 - 3.1.2 Global Drugs for Oncology Revenue Market Share by Players (2015-2020)
 - 3.1.3 Global Drugs for Oncology Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
- 3.2 Global Drugs for Oncology Market Concentration Ratio
 - 3.2.1 Global Drugs for Oncology Market Concentration Ratio (CR5 and HHI)
 - 3.2.2 Global Top 10 and Top 5 Companies by Drugs for Oncology Revenue in 2019
- 3.3 Drugs for Oncology Key Players Head office and Area Served
- 3.4 Key Players Drugs for Oncology Product Solution and Service
- 3.5 Date of Enter into Drugs for Oncology Market
- 3.6 Mergers & Acquisitions, Expansion Plans

4 COVID-19 IMPLICATIONS ON MARKET SIZE BY TYPE (2015-2026)

- 4.1 Global Drugs for Oncology Historic Market Size by Type (2015-2020)
- 4.2 Global Drugs for Oncology Forecasted Market Size by Type (2021-2026)

5 COVID-19 IMPLICATIONS ON MARKET SIZE BY APPLICATION (2015-2026)

- 5.1 Global Drugs for Oncology Market Size by Application (2015-2020)
- 5.2 Global Drugs for Oncology Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA IMPACT OF COVID-19

- 6.1 North America Drugs for Oncology Market Size (2015-2020)
- 6.2 Drugs for Oncology Key Players in North America (2019-2020)
- 6.3 North America Drugs for Oncology Market Size by Type (2015-2020)
- 6.4 North America Drugs for Oncology Market Size by Application (2015-2020)

7 EUROPE IMPACT OF COVID-19

- 7.1 Europe Drugs for Oncology Market Size (2015-2020)
- 7.2 Drugs for Oncology Key Players in Europe (2019-2020)
- 7.3 Europe Drugs for Oncology Market Size by Type (2015-2020)
- 7.4 Europe Drugs for Oncology Market Size by Application (2015-2020)

8 CHINA IMPACT OF COVID-19

- 8.1 China Drugs for Oncology Market Size (2015-2020)
- 8.2 Drugs for Oncology Key Players in China (2019-2020)
- 8.3 China Drugs for Oncology Market Size by Type (2015-2020)
- 8.4 China Drugs for Oncology Market Size by Application (2015-2020)

9 JAPAN IMPACT OF COVID-19

- 9.1 Japan Drugs for Oncology Market Size (2015-2020)
- 9.2 Drugs for Oncology Key Players in Japan (2019-2020)
- 9.3 Japan Drugs for Oncology Market Size by Type (2015-2020)
- 9.4 Japan Drugs for Oncology Market Size by Application (2015-2020)

10 SOUTHEAST ASIA IMPACT OF COVID-19

- 10.1 Southeast Asia Drugs for Oncology Market Size (2015-2020)
- 10.2 Drugs for Oncology Key Players in Southeast Asia (2019-2020)
- 10.3 Southeast Asia Drugs for Oncology Market Size by Type (2015-2020)
- 10.4 Southeast Asia Drugs for Oncology Market Size by Application (2015-2020)

11 INDIA IMPACT OF COVID-19

- 11.1 India Drugs for Oncology Market Size (2015-2020)
- 11.2 Drugs for Oncology Key Players in India (2019-2020)
- 11.3 India Drugs for Oncology Market Size by Type (2015-2020)
- 11.4 India Drugs for Oncology Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA IMPACT OF COVID-19

- 12.1 Central & South America Drugs for Oncology Market Size (2015-2020)
- 12.2 Drugs for Oncology Key Players in Central & South America (2019-2020)
- 12.3 Central & South America Drugs for Oncology Market Size by Type (2015-2020)

12.4 Central & South America Drugs for Oncology Market Size by Application (2015-2020)

13KEY PLAYERS PROFILES

13.1 Roche

- 13.1.1 Roche Company Details
- 13.1.2 Roche Business Overview and Its Total Revenue
- 13.1.3 Roche Drugs for Oncology Introduction
- 13.1.4 Roche Revenue in Drugs for Oncology Business (2015-2020))
- 13.1.5 Roche Recent Development and Reaction to COVID-19

13.2 Celgene

- 13.2.1 Celgene Company Details
- 13.2.2 Celgene Business Overview and Its Total Revenue
- 13.2.3 Celgene Drugs for Oncology Introduction
- 13.2.4 Celgene Revenue in Drugs for Oncology Business (2015-2020)
- 13.2.5 Celgene Recent Development and Reaction to COVID-19

13.3 Novartis

- 13.3.1 Novartis Company Details
- 13.3.2 Novartis Business Overview and Its Total Revenue
- 13.3.3 Novartis Drugs for Oncology Introduction
- 13.3.4 Novartis Revenue in Drugs for Oncology Business (2015-2020)
- 13.3.5 Novartis Recent Development and Reaction to COVID-19

13.4 Bristol-Myers Squibb

- 13.4.1 Bristol-Myers Squibb Company Details
- 13.4.2 Bristol-Myers Squibb Business Overview and Its Total Revenue
- 13.4.3 Bristol-Myers Squibb Drugs for Oncology Introduction
- 13.4.4 Bristol-Myers Squibb Revenue in Drugs for Oncology Business (2015-2020)
- 13.4.5 Bristol-Myers Squibb Recent Development and Reaction to COVID-19

13.5 Johnson & Johnson

- 13.5.1 Johnson & Johnson Company Details
- 13.5.2 Johnson & Johnson Business Overview and Its Total Revenue
- 13.5.3 Johnson & Johnson Drugs for Oncology Introduction
- 13.5.4 Johnson & Johnson Revenue in Drugs for Oncology Business (2015-2020)
- 13.5.5 Johnson & Johnson Recent Development and Reaction to COVID-19

13.6 Merck & Co.

- 13.6.1 Merck & Co. Company Details
- 13.6.2 Merck & Co. Business Overview and Its Total Revenue
- 13.6.3 Merck & Co. Drugs for Oncology Introduction

- 13.6.4 Merck & Co. Revenue in Drugs for Oncology Business (2015-2020)
- 13.6.5 Merck & Co. Recent Development and Reaction to COVID-19
- 13.7 AstraZeneca
 - 13.7.1 AstraZeneca Company Details
 - 13.7.2 AstraZeneca Business Overview and Its Total Revenue
 - 13.7.3 AstraZeneca Drugs for Oncology Introduction
 - 13.7.4 AstraZeneca Revenue in Drugs for Oncology Business (2015-2020)
 - 13.7.5 AstraZeneca Recent Development and Reaction to COVID-19
- 13.8 Pfizer
 - 13.8.1 Pfizer Company Details
 - 13.8.2 Pfizer Business Overview and Its Total Revenue
 - 13.8.3 Pfizer Drugs for Oncology Introduction
 - 13.8.4 Pfizer Revenue in Drugs for Oncology Business (2015-2020)
 - 13.8.5 Pfizer Recent Development and Reaction to COVID-19
- 13.9 Amgen
 - 13.9.1 Amgen Company Details
 - 13.9.2 Amgen Business Overview and Its Total Revenue
 - 13.9.3 Amgen Drugs for Oncology Introduction
 - 13.9.4 Amgen Revenue in Drugs for Oncology Business (2015-2020)
 - 13.9.5 Amgen Recent Development and Reaction to COVID-19
- 13.10 Eli Lilly
 - 13.10.1 Eli Lilly Company Details
 - 13.10.2 Eli Lilly Business Overview and Its Total Revenue
 - 13.10.3 Eli Lilly Drugs for Oncology Introduction
 - 13.10.4 Eli Lilly Revenue in Drugs for Oncology Business (2015-2020)
 - 13.10.5 Eli Lilly Recent Development and Reaction to COVID-19
- 13.11 AbbVie
 - 10.11.1 AbbVie Company Details
 - 10.11.2 AbbVie Business Overview and Its Total Revenue
 - 10.11.3 AbbVie Drugs for Oncology Introduction
 - 10.11.4 AbbVie Revenue in Drugs for Oncology Business (2015-2020)
 - 10.11.5 AbbVie Recent Development and Reaction to COVID-19
- 13.12 Takeda
 - 10.12.1 Takeda Company Details
 - 10.12.2 Takeda Business Overview and Its Total Revenue
 - 10.12.3 Takeda Drugs for Oncology Introduction
 - 10.12.4 Takeda Revenue in Drugs for Oncology Business (2015-2020)
 - 10.12.5 Takeda Recent Development and Reaction to COVID-19
- 13.13 Astellas

- 10.13.1 Astellas Company Details
- 10.13.2 Astellas Business Overview and Its Total Revenue
- 10.13.3 Astellas Drugs for Oncology Introduction
- 10.13.4 Astellas Revenue in Drugs for Oncology Business (2015-2020)
- 10.13.5 Astellas Recent Development and Reaction to COVID-19
- 13.14 Ipsen
 - 10.14.1 Ipsen Company Details
 - 10.14.2 Ipsen Business Overview and Its Total Revenue
 - 10.14.3 Ipsen Drugs for Oncology Introduction
 - 10.14.4 Ipsen Revenue in Drugs for Oncology Business (2015-2020)
 - 10.14.5 Ipsen Recent Development and Reaction to COVID-19
- 13.15 Sanofi
 - 10.15.1 Sanofi Company Details
 - 10.15.2 Sanofi Business Overview and Its Total Revenue
 - 10.15.3 Sanofi Drugs for Oncology Introduction
 - 10.15.4 Sanofi Revenue in Drugs for Oncology Business (2015-2020)
 - 10.15.5 Sanofi Recent Development and Reaction to COVID-19
- 13.16 Bayer
 - 10.16.1 Bayer Company Details
 - 10.16.2 Bayer Business Overview and Its Total Revenue
 - 10.16.3 Bayer Drugs for Oncology Introduction
 - 10.16.4 Bayer Revenue in Drugs for Oncology Business (2015-2020)
 - 10.16.5 Bayer Recent Development and Reaction to COVID-19
- 13.17 Biogen Idec
 - 10.17.1 Biogen Idec Company Details
 - 10.17.2 Biogen Idec Business Overview and Its Total Revenue
 - 10.17.3 Biogen Idec Drugs for Oncology Introduction
 - 10.17.4 Biogen Idec Revenue in Drugs for Oncology Business (2015-2020)
 - 10.17.5 Biogen Idec Recent Development and Reaction to COVID-19
- 13.18 Teva
 - 10.18.1 Teva Company Details
 - 10.18.2 Teva Business Overview and Its Total Revenue
 - 10.18.3 Teva Drugs for Oncology Introduction
 - 10.18.4 Teva Revenue in Drugs for Oncology Business (2015-2020)
 - 10.18.5 Teva Recent Development and Reaction to COVID-19
- 13.19 Otsuka
 - 10.19.1 Otsuka Company Details
 - 10.19.2 Otsuka Business Overview and Its Total Revenue
 - 10.19.3 Otsuka Drugs for Oncology Introduction

10.19.4 Otsuka Revenue in Drugs for Oncology Business (2015-2020)

10.19.5 Otsuka Recent Development and Reaction to COVID-19

13.20 Eisai

10.20.1 Eisai Company Details

10.20.2 Eisai Business Overview and Its Total Revenue

10.20.3 Eisai Drugs for Oncology Introduction

10.20.4 Eisai Revenue in Drugs for Oncology Business (2015-2020)

10.20.5 Eisai Recent Development and Reaction to COVID-19

13.21 Merck KGaA

10.21.1 Merck KGaA Company Details

10.21.2 Merck KGaA Business Overview and Its Total Revenue

10.21.3 Merck KGaA Drugs for Oncology Introduction

10.21.4 Merck KGaA Revenue in Drugs for Oncology Business (2015-2020)

10.21.5 Merck KGaA Recent Development and Reaction to COVID-19

13.22 Gilead Sciences

10.22.1 Gilead Sciences Company Details

10.22.2 Gilead Sciences Business Overview and Its Total Revenue

10.22.3 Gilead Sciences Drugs for Oncology Introduction

10.22.4 Gilead Sciences Revenue in Drugs for Oncology Business (2015-2020)

10.22.5 Gilead Sciences Recent Development and Reaction to COVID-19

14ANALYST'S VIEWPOINTS/CONCLUSIONS

15APPENDIX

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.2 Data Source

15.2 Disclaimer

15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Drugs for Oncology Key Market Segments

Table 2. Key Players Covered: Ranking by Drugs for Oncology Revenue

Table 3. Ranking of Global Top Drugs for Oncology Manufacturers by Revenue (US\$ Million) in 2019

Table 4. Global Drugs for Oncology Market Size Growth Rate by Type (US\$ Million): 2020 VS 2026

Table 5. Key Players of Chemotherapy

Table 6. Key Players of Targeted Therapy

Table 7. Key Players of Immunotherapy (Biologic Therapy)

Table 8. Key Players of Hormonal Therapy

Table 9. Key Players of Others

Table 10. COVID-19 Impact Global Market: (Four Drugs for Oncology Market Size Forecast Scenarios)

Table 11. Opportunities and Trends for Drugs for Oncology Players in the COVID-19 Landscape

Table 12. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis

Table 13. Key Regions/Countries Measures against Covid-19 Impact

Table 14. Proposal for Drugs for Oncology Players to Combat Covid-19 Impact

Table 15. Global Drugs for Oncology Market Size Growth by Application (US\$ Million): 2020 VS 2026

Table 16. Global Drugs for Oncology Market Size by Regions (US\$ Million): 2020 VS 2026

Table 17. Global Drugs for Oncology Market Size by Regions (2015-2020) (US\$ Million)

Table 18. Global Drugs for Oncology Market Share by Regions (2015-2020)

Table 19. Global Drugs for Oncology Forecasted Market Size by Regions (2021-2026) (US\$ Million)

Table 20. Global Drugs for Oncology Market Share by Regions (2021-2026)

Table 21. Market Top Trends

Table 22. Key Drivers: Impact Analysis

Table 23. Key Challenges

Table 24. Drugs for Oncology Market Growth Strategy

Table 25. Main Points Interviewed from Key Drugs for Oncology Players

Table 26. Global Drugs for Oncology Revenue by Players (2015-2020) (Million US\$)

Table 27. Global Drugs for Oncology Market Share by Players (2015-2020)

Table 28. Global Top Drugs for Oncology Players by Company Type (Tier 1, Tier 2 and

Tier 3) (based on the Revenue in Drugs for Oncology as of 2019)

Table 29. Global Drugs for Oncology by Players Market Concentration Ratio (CR5 and HHI)

Table 30. Key Players Headquarters and Area Served

Table 31. Key Players Drugs for Oncology Product Solution and Service

Table 32. Date of Enter into Drugs for Oncology Market

Table 33. Mergers & Acquisitions, Expansion Plans

Table 34. Global Drugs for Oncology Market Size by Type (2015-2020) (Million US\$)

Table 35. Global Drugs for Oncology Market Size Share by Type (2015-2020)

Table 36. Global Drugs for Oncology Revenue Market Share by Type (2021-2026)

Table 37. Global Drugs for Oncology Market Size Share by Application (2015-2020)

Table 38. Global Drugs for Oncology Market Size by Application (2015-2020) (Million US\$)

Table 39. Global Drugs for Oncology Market Size Share by Application (2021-2026)

Table 40. North America Key Players Drugs for Oncology Revenue (2019-2020) (Million US\$)

Table 41. North America Key Players Drugs for Oncology Market Share (2019-2020)

Table 42. North America Drugs for Oncology Market Size by Type (2015-2020) (Million US\$)

Table 43. North America Drugs for Oncology Market Share by Type (2015-2020)

Table 44. North America Drugs for Oncology Market Size by Application (2015-2020) (Million US\$)

Table 45. North America Drugs for Oncology Market Share by Application (2015-2020)

Table 46. Europe Key Players Drugs for Oncology Revenue (2019-2020) (Million US\$)

Table 47. Europe Key Players Drugs for Oncology Market Share (2019-2020)

Table 48. Europe Drugs for Oncology Market Size by Type (2015-2020) (Million US\$)

Table 49. Europe Drugs for Oncology Market Share by Type (2015-2020)

Table 50. Europe Drugs for Oncology Market Size by Application (2015-2020) (Million US\$)

Table 51. Europe Drugs for Oncology Market Share by Application (2015-2020)

Table 52. China Key Players Drugs for Oncology Revenue (2019-2020) (Million US\$)

Table 53. China Key Players Drugs for Oncology Market Share (2019-2020)

Table 54. China Drugs for Oncology Market Size by Type (2015-2020) (Million US\$)

Table 55. China Drugs for Oncology Market Share by Type (2015-2020)

Table 56. China Drugs for Oncology Market Size by Application (2015-2020) (Million US\$)

Table 57. China Drugs for Oncology Market Share by Application (2015-2020)

Table 58. Japan Key Players Drugs for Oncology Revenue (2019-2020) (Million US\$)

Table 59. Japan Key Players Drugs for Oncology Market Share (2019-2020)

Table 60. Japan Drugs for Oncology Market Size by Type (2015-2020) (Million US\$)

Table 61. Japan Drugs for Oncology Market Share by Type (2015-2020)

Table 62. Japan Drugs for Oncology Market Size by Application (2015-2020) (Million US\$)

Table 63. Japan Drugs for Oncology Market Share by Application (2015-2020)

Table 64. Southeast Asia Key Players Drugs for Oncology Revenue (2019-2020) (Million US\$)

Table 65. Southeast Asia Key Players Drugs for Oncology Market Share (2019-2020)

Table 66. Southeast Asia Drugs for Oncology Market Size by Type (2015-2020) (Million US\$)

Table 67. Southeast Asia Drugs for Oncology Market Share by Type (2015-2020)

Table 68. Southeast Asia Drugs for Oncology Market Size by Application (2015-2020) (Million US\$)

Table 69. Southeast Asia Drugs for Oncology Market Share by Application (2015-2020)

Table 70. India Key Players Drugs for Oncology Revenue (2019-2020) (Million US\$)

Table 71. India Key Players Drugs for Oncology Market Share (2019-2020)

Table 72. India Drugs for Oncology Market Size by Type (2015-2020) (Million US\$)

Table 73. India Drugs for Oncology Market Share by Type (2015-2020)

Table 74. India Drugs for Oncology Market Size by Application (2015-2020) (Million US\$)

Table 75. India Drugs for Oncology Market Share by Application (2015-2020)

Table 76. Central & South America Key Players Drugs for Oncology Revenue (2019-2020) (Million US\$)

Table 77. Central & South America Key Players Drugs for Oncology Market Share (2019-2020)

Table 78. Central & South America Drugs for Oncology Market Size by Type (2015-2020) (Million US\$)

Table 79. Central & South America Drugs for Oncology Market Share by Type (2015-2020)

Table 80. Central & South America Drugs for Oncology Market Size by Application (2015-2020) (Million US\$)

Table 81. Central & South America Drugs for Oncology Market Share by Application (2015-2020)

Table 82. Roche Company Details

Table 83. Roche Business Overview

Table 84. Roche Product

Table 85. Roche Revenue in Drugs for Oncology Business (2015-2020) (Million US\$)

Table 86. Roche Recent Development

Table 87. Celgene Company Details

- Table 88. Celgene Business Overview
- Table 89. Celgene Product
- Table 90. Celgene Revenue in Drugs for Oncology Business (2015-2020) (Million US\$)
- Table 91. Celgene Recent Development
- Table 92. Novartis Company Details
- Table 93. Novartis Business Overview
- Table 94. Novartis Product
- Table 95. Novartis Revenue in Drugs for Oncology Business (2015-2020) (Million US\$)
- Table 96. Novartis Recent Development
- Table 97. Bristol-Myers Squibb Company Details
- Table 98. Bristol-Myers Squibb Business Overview
- Table 99. Bristol-Myers Squibb Product
- Table 100. Bristol-Myers Squibb Revenue in Drugs for Oncology Business (2015-2020) (Million US\$)
- Table 101. Bristol-Myers Squibb Recent Development
- Table 102. Johnson & Johnson Company Details
- Table 103. Johnson & Johnson Business Overview
- Table 104. Johnson & Johnson Product
- Table 105. Johnson & Johnson Revenue in Drugs for Oncology Business (2015-2020) (Million US\$)
- Table 106. Johnson & Johnson Recent Development
- Table 107. Merck & Co. Company Details
- Table 108. Merck & Co. Business Overview
- Table 109. Merck & Co. Product
- Table 110. Merck & Co. Revenue in Drugs for Oncology Business (2015-2020) (Million US\$)
- Table 111. Merck & Co. Recent Development
- Table 112. AstraZeneca Company Details
- Table 113. AstraZeneca Business Overview
- Table 114. AstraZeneca Product
- Table 115. AstraZeneca Revenue in Drugs for Oncology Business (2015-2020) (Million US\$)
- Table 116. AstraZeneca Recent Development
- Table 117. Pfizer Business Overview
- Table 118. Pfizer Product
- Table 119. Pfizer Company Details
- Table 120. Pfizer Revenue in Drugs for Oncology Business (2015-2020) (Million US\$)
- Table 121. Pfizer Recent Development
- Table 122. Amgen Company Details

Table 123. Amgen Business Overview

Table 124. Amgen Product

Table 125. Amgen Revenue in Drugs for Oncology Business (2015-2020) (Million US\$)

Table 126. Amgen Recent Development

Table 127. Eli Lilly Company Details

Table 128. Eli Lilly Business Overview

Table 129. Eli Lilly Product

Table 130. Eli Lilly Revenue in Drugs for Oncology Business (2015-2020) (Million US\$)

Table 131. Eli Lilly Recent Development

Table 132. AbbVie Company Details

Table 133. AbbVie Business Overview

Table 134. AbbVie Product

Table 135. AbbVie Revenue in Drugs for Oncology Business (2015-2020) (Million US\$)

Table 136. AbbVie Recent Development

Table 137. Takeda Company Details

Table 138. Takeda Business Overview

Table 139. Takeda Product

Table 140. Takeda Revenue in Drugs for Oncology Business (2015-2020) (Million US\$)

Table 141. Takeda Recent Development

Table 142. Astellas Company Details

Table 143. Astellas Business Overview

Table 144. Astellas Product

Table 145. Astellas Revenue in Drugs for Oncology Business (2015-2020) (Million US\$)

Table 146. Astellas Recent Development

Table 147. Ipsen Company Details

Table 148. Ipsen Business Overview

Table 149. Ipsen Product

Table 150. Ipsen Revenue in Drugs for Oncology Business (2015-2020) (Million US\$)

Table 151. Ipsen Recent Development

Table 152. Sanofi Company Details

Table 153. Sanofi Business Overview

Table 154. Sanofi Product

Table 155. Sanofi Revenue in Drugs for Oncology Business (2015-2020) (Million US\$)

Table 156. Sanofi Recent Development

Table 157. Bayer Company Details

Table 158. Bayer Business Overview

Table 159. Bayer Product

Table 160. Bayer Revenue in Drugs for Oncology Business (2015-2020) (Million US\$)

Table 161. Bayer Recent Development

Table 162. Biogen Idec Company Details

Table 163. Biogen Idec Business Overview

Table 164. Biogen Idec Product

Table 165. Biogen Idec Revenue in Drugs for Oncology Business (2015-2020) (Million US\$)

Table 166. Biogen Idec Recent Development

Table 167. Teva Company Details

Table 168. Teva Business Overview

Table 169. Teva Product

Table 170. Teva Revenue in Drugs for Oncology Business (2015-2020) (Million US\$)

Table 171. Teva Recent Development

Table 172. Otsuka Company Details

Table 173. Otsuka Business Overview

Table 174. Otsuka Product

Table 175. Otsuka Revenue in Drugs for Oncology Business (2015-2020) (Million US\$)

Table 176. Otsuka Recent Development

Table 177. Eisai Company Details

Table 178. Eisai Business Overview

Table 179. Eisai Product

Table 180. Eisai Revenue in Drugs for Oncology Business (2015-2020) (Million US\$)

Table 181. Eisai Recent Development

Table 182. Merck KGaA Company Details

Table 183. Merck KGaA Business Overview

Table 184. Merck KGaA Product

Table 185. Merck KGaA Revenue in Drugs for Oncology Business (2015-2020) (Million US\$)

Table 186. Merck KGaA Recent Development

Table 187. Gilead Sciences Company Details

Table 188. Gilead Sciences Business Overview

Table 189. Gilead Sciences Product

Table 190. Gilead Sciences Revenue in Drugs for Oncology Business (2015-2020) (Million US\$)

Table 191. Gilead Sciences Recent Development

Table 192. Research Programs/Design for This Report

Table 193. Key Data Information from Secondary Sources

Table 194. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

- Figure 1. Global Drugs for Oncology Market Share by Type: 2020 VS 2026
- Figure 2. Chemotherapy Features
- Figure 3. Targeted Therapy Features
- Figure 4. Immunotherapy (Biologic Therapy) Features
- Figure 5. Hormonal Therapy Features
- Figure 6. Others Features
- Figure 7. Global Drugs for Oncology Market Share by Application: 2020 VS 2026
- Figure 8. Blood Cancer Case Studies
- Figure 9. Breast Cancer Case Studies
- Figure 10. Gastrointestinal Cancer Case Studies
- Figure 11. Prostate Cancer Case Studies
- Figure 12. Respiratory/Lung Cancer Case Studies
- Figure 13. Others Case Studies
- Figure 14. Drugs for Oncology Report Years Considered
- Figure 15. Global Drugs for Oncology Market Size YoY Growth 2015-2026 (US\$ Million)
- Figure 16. Global Drugs for Oncology Market Share by Regions: 2020 VS 2026
- Figure 17. Global Drugs for Oncology Market Share by Regions (2021-2026)
- Figure 18. Porter's Five Forces Analysis
- Figure 19. Global Drugs for Oncology Market Share by Players in 2019
- Figure 20. Global Top Drugs for Oncology Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Drugs for Oncology as of 2019)
- Figure 21. The Top 10 and 5 Players Market Share by Drugs for Oncology Revenue in 2019
- Figure 22. North America Drugs for Oncology Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 23. Europe Drugs for Oncology Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 24. China Drugs for Oncology Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 25. Japan Drugs for Oncology Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 26. Southeast Asia Drugs for Oncology Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 27. India Drugs for Oncology Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 28. Central & South America Drugs for Oncology Market Size YoY Growth

(2015-2020) (Million US\$)

Figure 29. Roche Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 30. Roche Revenue Growth Rate in Drugs for Oncology Business (2015-2020)

Figure 31. Celgene Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 32. Celgene Revenue Growth Rate in Drugs for Oncology Business (2015-2020)

Figure 33. Novartis Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 34. Novartis Revenue Growth Rate in Drugs for Oncology Business (2015-2020)

Figure 35. Bristol-Myers Squibb Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 36. Bristol-Myers Squibb Revenue Growth Rate in Drugs for Oncology Business (2015-2020)

Figure 37. Johnson & Johnson Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 38. Johnson & Johnson Revenue Growth Rate in Drugs for Oncology Business (2015-2020)

Figure 39. Merck & Co. Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 40. Merck & Co. Revenue Growth Rate in Drugs for Oncology Business (2015-2020)

Figure 41. AstraZeneca Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 42. AstraZeneca Revenue Growth Rate in Drugs for Oncology Business (2015-2020)

Figure 43. Pfizer Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 44. Pfizer Revenue Growth Rate in Drugs for Oncology Business (2015-2020)

Figure 45. Amgen Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 46. Amgen Revenue Growth Rate in Drugs for Oncology Business (2015-2020)

Figure 47. Eli Lilly Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 48. Eli Lilly Revenue Growth Rate in Drugs for Oncology Business (2015-2020)

Figure 49. AbbVie Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 50. AbbVie Revenue Growth Rate in Drugs for Oncology Business (2015-2020)

Figure 51. Takeda Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 52. Takeda Revenue Growth Rate in Drugs for Oncology Business (2015-2020)

Figure 53. Astellas Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 54. Astellas Revenue Growth Rate in Drugs for Oncology Business (2015-2020)

Figure 55. Ipsen Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 56. Ipsen Revenue Growth Rate in Drugs for Oncology Business (2015-2020)

Figure 57. Sanofi Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 58. Sanofi Revenue Growth Rate in Drugs for Oncology Business (2015-2020)

Figure 59. Bayer Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 60. Bayer Revenue Growth Rate in Drugs for Oncology Business (2015-2020)

Figure 61. Biogen Idec Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 62. Biogen Idec Revenue Growth Rate in Drugs for Oncology Business (2015-2020)

Figure 63. Teva Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 64. Teva Revenue Growth Rate in Drugs for Oncology Business (2015-2020)

Figure 65. Otsuka Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 66. Otsuka Revenue Growth Rate in Drugs for Oncology Business (2015-2020)

Figure 67. Eisai Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 68. Eisai Revenue Growth Rate in Drugs for Oncology Business (2015-2020)

Figure 69. Bottom-up and Top-down Approaches for This Report

Figure 70. Data Triangulation

Figure 71. Key Executives Interviewed

I would like to order

Product name: Covid-19 Impact on Global Drugs for Oncology Market Size, Status and Forecast 2020-2026

Product link: <https://marketpublishers.com/r/CC07D7E2A923EN.html>

Price: US\$ 3,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CC07D7E2A923EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

